MARKET

BVXV

BVXV

BiondVax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.240
-0.120
-5.08%
After Hours: 2.330 +0.09 +4.02% 18:23 09/24 EDT
OPEN
2.345
PREV CLOSE
2.360
HIGH
2.360
LOW
2.200
VOLUME
87.41K
TURNOVER
--
52 WEEK HIGH
43.57
52 WEEK LOW
2.100
MARKET CAP
32.10M
P/E (TTM)
5.29
1D
5D
1M
3M
1Y
5Y
Cathie Wood Is Selling These 10 Stocks
In this article, we discuss the 10 stocks Cathie Wood is selling. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood Is Selling These 5 Stocks. There are few institutional investors who are willing to take risks on high g...
Insider Monkey · 09/15 12:59
BRIEF-BiondVax Announces Second Quarter 2021 Financial Results And Provides Business Update
reuters.com · 08/26 20:22
BiondVax Pharmaceuticals Q2 EPS $(0.10) Down From $(0.03) YoY
BiondVax Pharmaceuticals (NASDAQ:BVXV) reported quarterly losses of $(0.10) per share. This is a 233.33 percent decrease over losses of $(0.03) per share from the same period last year.
Benzinga · 08/26 20:12
BiondVax Pharmaceuticals Trims Q2 Net Loss From Same Quarter in 2020
MT Newswires · 08/26 16:50
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
PayPal Holdings, Anheuser-Busch InBev, Uber Technologies among premarket losers' pack
Annovis Bio, Inc. ANVS -53% after presenting Alzheimer's drug data at AAIC 2021. Atreca, Inc. (NASDAQ:BCEL) -29% after presents initial clinical data from Phase 1b trial of ATRC-101 in select advanced solid tumors.
Seekingalpha · 07/29 12:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BVXV. Analyze the recent business situations of BiondVax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BVXV stock price target is 81.00 with a high estimate of 81.00 and a low estimate of 81.00.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 338.94K
% Owned: 2.36%
Shares Outstanding: 14.33M
TypeInstitutionsShares
Increased
5
17.27K
New
3
106.71K
Decreased
1
566
Sold Out
6
95.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Mark Germain
Chief Executive Officer/President/Director
Ron Babecoff
Chief Financial Officer
Uri Ben-Or
Chief Scientific Officer
Tamar Ben-Yedidia
Other
Yisrael Gewirtz
Director
George Lowell
Director
Yael Margolin
Director
Samuel Moed
Director
Adi Raviv
Director
Jack Rosen
Director
Avner Rotman
Non-Executive Director
Irit Ben-Ami
Independent Director
Ruth Ben Yakar
No Data
  • All
  • Financials
  • Insiders
More
About BVXV
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BVXV stock methods without spending real money on the virtual paper trading platform.